Current and future approaches in the prevention and treatment of diabetic retinopathy
- PMID: 19668733
- PMCID: PMC2693984
- DOI: 10.2147/opth.s736
Current and future approaches in the prevention and treatment of diabetic retinopathy
Abstract
Diabetic retinopathy (DR) is a major cause of blindness worldwide and is the number one cause of blindness in working-age individuals in developed countries. We review the current literature and discuss the pathogenesis, modifying risk factors, genetics, and treatment of DR. Special focus is placed on the rationale and effectiveness of therapeutic modalities, both current and future.
References
-
- Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118:445–50. - PubMed
-
- Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480–7. - PubMed
-
- Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes. 1997;46:1473–80. - PubMed
-
- Aiello LP. The potential role of PKC beta in diabetic retinopathy and macular edema. Surv Ophthalmol. 2002;47(Suppl 2):S263–269. - PubMed
-
- Aiello LP, Davis MD, Girach A, et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology. 2006;113:2221–30. - PubMed
LinkOut - more resources
Full Text Sources
